...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004
【24h】

Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004

机译：2003年至2004年期间，三价冷适应型流感病毒疫苗对A型流感（福建）的变种的功效

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In the 2003-2004 influenza season, the predominant circulating influenza A (H3N2) virus in the United States was similar antigenically to A/Fujian/411/2002 (H3N2), a drift variant of A/Panama/2007/99 (H3N2), the vaccine strain. That year, a field study of trivalent live-attenuated influenza vaccine (LAIV-T) was conducted in Temple-Belton, Texas, as part of a larger community-based, non-randomized, open-label study in three communities that began in August 1998 [Gaglani MJ, Piedra PA, Herschler GB, Griffith ME, Kozinetz CA, Riggs MW, et al. Direct effectiveness of the trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against the 2000-2001 influenza A (H1N1) and B epidemic in healthy children. Arch Pediatr Adolesc Med 2004;158:65-73; Piedra PA, Gaglani MJ, Kozinetz CA, Herschler G, Riggs M, Griffith M, et al. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine 2005;23:1540-8; Piedra PA, Gaglani MJ, Riggs M, Herschler G, Fewlass C, Watts M, et al. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. Pediatrics 2005;116:397-407]. Participants were healthy children aged 5-18 years. The analysis here concerns 6403 children in the Scott & White Health Plan (SWHP) database living within zip codes of the Temple-Belton area, of whom 1706 received LAIV-T and 548 received trivalent inactivated vaccine (TIV) in 2003, 983 had been previously vaccinated in 1998-2001, but not in 2002-2003 or 2003, and 3166 had never been vaccinated. The main outcome measure was medically-attended acute respiratory illness (MAARI). Surveillance culture results were incorporated into the analysis to estimate efficacy against culture-confirmed influenza illness. Vaccine effectiveness of LAIV-T against MAARI was 26% (95% confidence interval (CI) 11, 39). Vaccine efficacy of LAIV-T against culture-confirmed influenza illness including surveillance cultures of children in the SWHP database in the validation calculation was 56% (95% CI 24, 84). LAIV-T was cross-protective with a drift variant strain in 2003-2004, evidence that such vaccines could be important for preparing for a pandemic and for annual influenza.
机译：在2003-2004流感季节，美国主要的流行性甲型流感（H3N2）病毒在抗原性上类似于A / Panama / 2007/99（H3N2）的变种A / Fujian / 411/2002（H3N2）。 ，疫苗株。那年，在德克萨斯州的坦普尔-贝尔顿市进行了三价减毒活疫苗（LAIV-T）的现场研究，这是一项较大的基于社区，非随机，开放标签的研究的一部分，该研究始于2006年。 1998年8月[Gaglani MJ，Piedra PA，Herschler GB，Griffith ME，Kozinetz CA，Riggs MW等。在健康儿童中，三价冷适应型流感病毒疫苗（CAIV-T）对2000-2001年甲型和乙型流感流行的直接效果。 Arch Pediatr Adolesc Med 2004; 158：65-73; Piedra PA，Gaglani MJ，Kozinetz CA，Herschler G，Riggs M，Griffith M等。在儿童中使用三价减毒活疫苗（CAIV-T），可抵抗成年人的流感相关疾病，从而具有成群免疫力。疫苗2005; 23：1540-8; Piedra PA，Gaglani MJ，Riggs M，Herschler G，Fewlass C，Watts M等。在一项基于社区的非随机开放标签试验中，三价减毒活疫苗在18个月至4岁，5至9岁和10至18岁的健康儿童中是安全的。 Pediatrics 2005; 116：397-407]。参加者为5-18岁的健康儿童。此处的分析涉及斯科特与怀特健康计划（SWHP）数据库中的6403名儿童，他们居住在Temple-Belton地区的邮政编码内，其中1706例接受了LAIV-T，548例接受了三价灭活疫苗（TIV），其中983例接受了以前曾在1998-2001年接种过疫苗，但在2002-2003或2003年未接种过疫苗，从未接种过3166疫苗。主要结局指标为医疗照护急性呼吸道疾病（MAARI）。监测培养结果被纳入分析中，以评估对培养证实的流感疾病的疗效。 LAIV-T对抗MAARI的疫苗有效率为26％（95％置信区间（CI）11、39）。在验证计算中，LAIV-T对文化确认的流感疾病（包括SWHP数据库中的儿童监测文化）的疫苗效力为56％（95％CI 24，84）。在2003-2004年间，LAIV-T与一种变异株具有交叉保护作用，这证明此类疫苗对于大流行和年度流感的预防可能很重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号